Cardiac Marker Analyzer Market - Forecasts from 2018 to 2023

July 2018 | 92 pages | ID: CBD95445F7DEN
Knowledge Sourcing Intelligence LLP

Abstracts

Cardiac marker analyzer market was valued at US$1,356.125 million in 2017 and is projected to expand at a CAGR of 4.84% over the forecast period to reach US$1,800.905 million by 2023. Cardiac market analyzer is used in the diagnosis of myocardial infarction and other cardiac-related diseases by measuring levels of various cardiac biomarkers. Rising prevalence of cardiovascular diseases owing to growing global geriatric population and lifestyle-related diseases is driving the demand for cardiac marker analyzers worldwide. Rising investments in R&D to develop innovative applications of cardiac marker analyzers and ongoing clinical trials to identify novel cardiac biomarkers will further fuel the growth of cardiac biomarker analyzer market. However, factors such as technical problems related to sample collection and regulatory and reimbursement issues are restraining the growth of cardiac marker analyzer market. Geographically, APAC will witness a significant market growth owing to the increasing cases of cardiovascular diseases and booming medical tourism industry, particularly in Southeast Asian countries.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the cardiac marker analyzer value chain. Last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the Cardiac Marker Analyzer market.

Major industry players profiled as part of the report are Radiometer Medical APS, CardioGenics Inc., Roche Diagnostics International Ltd, Abbott Rapid Diagnostics, and Beckman Coulter, Inc. among others.

Segmentation

Cardiac marker analyzer market has been analyzed through following segments:

• By Type of Cardiac Marker
• Troponin
• Creatine Kinase
• Myoblobin
• Others
• By End User
• Hospitals and Clinics
• Laboratories
• Ambulatory Surgical Centers
• By Geography
• North America

Ø U.S.
Ø Canada
Ø Mexico
Ø Others

• South America

Ø Brazil
Ø Argentina
Ø Others

• Europe

Ø UK
Ø Germany
Ø France
Ø Others

• Middle East and Africa

Ø Saudi Arabia
Ø UAE
Ø Israel
Ø Others

• Asia-Pacific

Ø Japan
Ø China
Ø India
Ø Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Product Pipeline
4.7. Life Cycle Analysis - Regional Snapshot
4.8. Market Attractiveness

5. CARDIAC MARKER ANALYZER MARKET BY TYPE OF CARDIAC MARKER

5.1. Troponin
5.2. Creatine Kinase
5.3. Myoblobin
5.4. Others

6. CARDIAC MARKER ANALYZER MARKET BY END USER

6.1. Hospitals and Clinics
6.2. Laboratories
6.3. Ambulatory Surgical Centers

7. CARDIAC MARKER ANALYZER MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. U.S.
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. UK
  7.3.2. Germany
  7.3.3. France
  7.3.4. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. UAE
  7.4.3. Israel
  7.4.4. Others
7.5. Asia-Pacific
  7.5.1. Japan
  7.5.2. China
  7.5.3. India
  7.5.4. Others

8. COMPETITIVE INTELLIGENCE

8.1. Recent Deals and Investment
8.2. Strategies of Key Players
8.3. Investment Analysis

9. COMPANY PROFILES

9.1. Radiometer Medical APS
9.2. CardioGenics Inc.
9.3. Roche Diagnostics International Ltd
9.4. Abbott Rapid Diagnostics
9.5. Beckman Coulter, Inc.
9.6. Siemens Healthcare GmbH
9.7. LSI Medience Corporation
LIST OF FIGURES
LIST OF TABLES
DISCLAIMER